Richard A. Larson

Richard A. Larson

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Richard A. Larson

University of Chicago, Chicago, IL

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
HDHartmut Döhner
Hartmut Döhner
Andrew H WeiAndrew H Wei
Andrew H Wei
FAFrederick R. Appelbaum
Frederick R. Appelbaum
CCCharles Craddock
Charles Craddock
CDCourtney Dinardo
Courtney Dinardo
BLBob Löwenberg
Bob Löwenberg
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

7 December 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
BDBrian J. Druker
Brian J. Druker
François GuilhotFrançois Guilhot
François Guilhot
SOStephen G. O'Brien
Stephen G. O'Brien
IGInsa Gathmann
Insa Gathmann
HKHagop Kantarjian
Hagop Kantarjian
RLRichard A. Larson
Richard A. Larson
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. The median follow-up was 60 months. Kaplan–Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343.)

15 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
DADaniel A. Arber
Daniel A. Arber
AOAttilio Orazi
Attilio Orazi
RHRobert P. Hasserjian
Robert P. Hasserjian
MBMichael J. Borowitz
Michael J. Borowitz
KCKatherine R. Calvo
Katherine R. Calvo
ATAyalew Tefferi
Ayalew Tefferi
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.

21 January 2010 in Blood
Verified
Journal Article
Closed access
PDF file
HDHartmut Döhner
Hartmut Döhner
EEElihu H. Estey
Elihu H. Estey
SASergio Amadori
Sergio Amadori
FAFrederick R. Appelbaum
Frederick R. Appelbaum
TBThomas Büchner
Thomas Büchner
CBClara D. Bloomfield
Clara D. Bloomfield
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion–based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

13 March 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SOStephen G. O'Brien
Stephen G. O'Brien
François GuilhotFrançois Guilhot
François Guilhot
RLRichard A. Larson
Richard A. Larson
IGInsa Gathmann
Insa Gathmann
MBMichele Baccarani
Michele Baccarani
BDBrian J. Druker
Brian J. Druker
Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates of progression. After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy. In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.

15 December 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BCBruce D. Cheson
Bruce D. Cheson
JBJohn M. Bennett
John M. Bennett
KKKenneth J. Kopecky
Kenneth J. Kopecky
TBThomas Büchner
Thomas Büchner
CWCheryl L. Willman
Cheryl L. Willman
CBClara D. Bloomfield
Clara D. Bloomfield
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders.